David J. Sugarbaker

Active 1984–2020

124
Papers
35,470
Citations
93
h-index
123
i10-index

Citations

Citations per year for David J. Sugarbaker1981: 2 citations1991: 6 citations1992: 4 citations1993: 7 citations1994: 26 citations1995: 67 citations1996: 63 citations1997: 75 citations1998: 107 citations1999: 101 citations2000: 87 citations2001: 138 citations2002: 162 citations2003: 208 citations2004: 254 citations2005: 290 citations2006: 312 citations2007: 314 citations2008: 360 citations2009: 395 citations2010: 427 citations2011: 416 citations2012: 381 citations2013: 370 citations2014: 353 citations2015: 309 citations2016: 306 citations2017: 238 citations2018: 222 citations2019: 677 citations2020: 659 citations2021: 579 citations2022: 320 citations2023: 223 citations2024: 384 citations2025: 130 citations2026: 7 citations1982–1990: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,932 citing papers, 33% of this breakdownChina: 955 citing papers, 8% of this breakdownUnited Kingdom: 739 citing papers, 6.2% of this breakdownJapan: 579 citing papers, 4.9% of this breakdownItaly: 528 citing papers, 4.4% of this breakdownGermany: 510 citing papers, 4.3% of this breakdownCanada: 506 citing papers, 4.3% of this breakdownFrance: 400 citing papers, 3.4% of this breakdownAustralia: 372 citing papers, 3.1% of this breakdownNetherlands: 344 citing papers, 2.9% of this breakdownSpain: 270 citing papers, 2.3% of this breakdownSwitzerland: 240 citing papers, 2% of this breakdown
0%33%Other 21.2%

Fields

  • Medicine62.1%
  • Biochemistry, Genetics and Molecular Biology28.5%
  • Computer Science3.4%
  • Immunology and Microbiology2.4%
  • Engineering0.7%
  • Neuroscience0.6%
  • Other2.3%

Topics

  • Lung Cancer Diagnosis and Treatment5.5%
  • Lung Cancer Treatments and Mutations5.1%
  • Gene expression and cancer classification4.1%
  • Occupational and environmental lung diseases3.1%
  • Pleural and Pulmonary Diseases3.1%
  • Lung Cancer Research Studies2.4%
  • Other76.7%

Coauthors

All papers

Open in search
  1. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Genetics 2016 cited by 925

  2. Derivation and Prospective Validation of a Simple Index for Prediction of Cardiac Risk of Major Noncardiac Surgery

    Authors: , , , , , , , , , , , , - Circulation 1999 cited by 3,732

  3. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses

    Authors: , , , , , , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2001 cited by 2,586

  4. Aging and Environmental Exposures Alter Tissue-Specific DNA Methylation Dependent upon CpG Island Context

    Authors: , , , , , , , , , , , , , - PLoS Genetics 2009 cited by 1,094

  5. Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non–Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups

    Authors: , , , , , , , , , , , - Journal of Clinical Oncology 2008 cited by 990

  6. EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2008 cited by 983

  7. Functional Expression and Mutations of c-Met and Its Therapeutic Inhibition with SU11274 and Small Interfering RNA in Non–Small Cell Lung Cancer

    Authors: , , , , , , , , , , , , , , - Cancer Research 2005 cited by 578

  8. K-ras activation generates an inflammatory response in lung tumors

    Authors: , , , , , , , , , , , , , , , - Oncogene 2005 cited by 267

  9. Lumpectomy plus Tamoxifen with or without Irradiation in Women 70 Years of Age or Older with Early Breast Cancer

    Authors: , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2004 cited by 1,079

  10. Phase III Trial of Trimodality Therapy With Cisplatin, Fluorouracil, Radiotherapy, and Surgery Compared With Surgery Alone for Esophageal Cancer: CALGB 9781

    Authors: , , , , , , , , , - Journal of Clinical Oncology 2008 cited by 1,358

  11. Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma.

    Authors: , , , , , , , , - 2002 cited by 881

  12. Activating Mutations of the Noonan Syndrome-Associated SHP2/PTPN11 Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , - Cancer Research 2004 cited by 513

  13. Relationship between margin distance and local recurrence among patients undergoing wedge resection for small (≤2 cm) non–small cell lung cancer

    Authors: , , , , , , , , , , - Journal of Thoracic and Cardiovascular Surgery 2014 cited by 161

  14. The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups

    Authors: , , , , , , , , , , , , , - Journal of Thoracic and Cardiovascular Surgery 2012 cited by 608

  15. Pleurectomy Decortication in the Treatment of Malignant Pleural Mesothelioma

    Authors: , , , , , , , - Annals of Surgery 2020 cited by 46

  16. Phase III Intergroup Study of Talc Poudrage vs Talc Slurry Sclerosis for Malignant Pleural Effusion

    Authors: , , , , , , , , , , , , - CHEST Journal 2005 cited by 581

  17. Multicenter Phase II Trial of Neoadjuvant Pemetrexed Plus Cisplatin Followed by Extrapleural Pneumonectomy and Radiation for Malignant Pleural Mesothelioma

    Authors: , , , , , , , , , , , - Journal of Clinical Oncology 2009 cited by 464

  18. Nitric Oxide Synthase in Human and Rat Lung: Immunocytochemical and Histochemical Localization

    Authors: , , , , , , - American Journal of Respiratory Cell and Molecular Biology 1993 cited by 818

  19. Functional Analysis of c-Met/Hepatocyte Growth Factor Pathway in Malignant Pleural Mesothelioma

    Authors: , , , , , , , , , , , , , , , , , - Cancer Research 2006 cited by 196

  20. Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection

    Authors: , , , , , , , - Journal of Thoracic and Cardiovascular Surgery 2013 cited by 165

  21. Phase I to II Study of Pleurectomy/Decortication and Intraoperative Intracavitary Hyperthermic Cisplatin Lavage for Mesothelioma

    Authors: , , , , , , , , , , - Journal of Clinical Oncology 2006 cited by 222

  22. Extrapleural Pneumonectomy in the Treatment of Epithelioid Malignant Pleural Mesothelioma

    Authors: , , - Annals of Surgery 2014 cited by 111

  23. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients

    Authors: , , , , , , , , , , , - Journal of Thoracic and Cardiovascular Surgery 1999 cited by 986

  24. Similar Long-term Survival of Elderly Patients With Non-small Cell Lung Cancer Treated With Lobectomy or Wedge Resection Within the Surveillance, Epidemiology, and End Results Database

    Authors: , , , , , , - CHEST Journal 2005 cited by 335